Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Waiting for you to step up to the podium falconer.
Batten disease is a killer.
Classic forms of Batten
Batten form Age of onset End of life
Infantile 6 months to 2 years old Mid-childhood
Late Infantile 2 to 4 years old 8 to 10 years old
Juvenile 5 to 10 years old Late teens to early 20s
Adult 25 to 43 years old Normal lifespan
And Batten disease is new, isn't it?
“The really exciting part is that there is extremely promising pre-clinical data that shows the drug has a strong possibility to work in other similar autism spectrum disorders, like Batten disease, Fragile X, Angelman syndrome and infantile spasms.” Dr. Missling stated in an exclusive interview.
This is my favorite part.
The company is planning to meet with the FDA to discuss steps to approval
On Bigcharts.com( which is free) go to advanced chart, in the upper indicators dropdown box is "volume by price".
"We are likely at a point where every simple little nuance has meaningful consequences."
I think you have a future as a tv series writer!
Well said.
Is this the answer you're looking for?
I'm hoping it is!
https://www.marketwatch.com/press-release/anavex-life-sciences-to-present-at-the-evercore-isi-3rd-annual-healthconx-conference-2020-11-25?siteid=bigcharts&dist=bigcharts&tesla=y
Interesting video on statistical significance.
[ Patients themselves may be expressing excitement/or not.]
I've pondered on this for some time.
If I were diagnosed with mild/moderate Alzheimer's and participated in a A2-73 trial and got better I would likely shout it from the rooftops.
And no one(except someone with someone in a similar predicament, of which I currently know none) would really notice/care.
They would likely think I was misdiagnosed, self misdiagnosed, having a cognizant stretch or probably just say "How nice for you".
I think very few people are influencers.
Another of his quotes:
Traders who can both be right and sit tight are uncommon. I found it one of the hardest things to learn. But it is only after a stock operator has firmly grasped this that he can make the big money.”
And this probably makes you scoff.
"Treatment with Anavex 2-73 also led to significant improvements in patients’ cognitive skills, including choice reaction time, vigilance, and episodic memory, potentially benefitting quality of life."
These are the two things I feel I know for certain.
1.) Anavex is wary of lawsuits as evidenced but their cautiousness after the earlier spate of lawsuits.
2.) Anavex announced results showing clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research computerized assessment system analysis.
Call me biased but I like your post better than his.
Well at least your message is consistent.
Could sleep be the common denominator that makes the CTAD presentation pertinent?
You beat the de-risking drum for months and months.
I insist you do so at the opening bell.
One more question if I might, when do we get to know the content of the presentation?
What are your conclusions?
Do we know for a fact this is a coveted spot or is it just a last minute spot created in the only time available?
It would be nice if A2-73 could help these people.
https://bgr.com/2020/11/02/coronavirus-symptoms-severe-brain-long-term-side-effects/
How do you think a company raises money? Magic beans?
My wife says I sometimes have tire tracks on the top of my head.
Here's another set.
13th Clinical Trials on Alzheimer's Disease (CTAD) November 4-7, 2020 - DIGITAL EVENT.
In my minds eye I pictured a conference center full of scientists, media,...
But of course it'll be digital this year.
I don't think it matters if they have Zero new Alz data.
CTAD says they are worthy of presenting there.
I think therefore I am.
That's how I feel about next Friday.
Anavex feels they have such compelling PDD trial results they requested a spot at an upcoming major Alzheimer's conference.
The CTAD, which is in no way, shape, or form beholding to Anavex, agreed and gave them a LB slot.
As Yoda might say "Bad news it cannot be".
I didn't mean it to sound like I was dissing your post.
Just wondering out loud why the good people of Australia aren't spreading the word.
"Just show folks like Ern Heaven and the painter and piano player and patients and families will ask for the drug."
They have been doing this for years in Australia.
Usually encompassed in a news story.
It's where we get such fodder.
And with some effort it's available to sufferers.
And there's probably an additional 100+ in OLE.
I don't see any groundswell.
That's the equivalent of a self fulfilling prophecy.
Because his remarks are read closely, they must remain somewhat neutral.
Same goes for Dr. Missling(lawsuits), politicians, and the fed chairman to mention a few.
He could very well be shouting "Holy cow!).
"Otherwise it would open CTAD for any dementia related company to present late breaking info."
This would be a good thing.
As the saying goes "science advances one funeral at a time".
"I was more confident in the Rett outcome than in PDD but that obviously changed with the PR and upcoming presentation."
I agree.
If one believes in Dr. Missling than Rett consistently being "first up to the plate" is a tell.
I fear we'll come out of the CTAD still in the shadows.
I'm planning to hang around college campuses and sell it in lieu of Ritalin.
Glad to hear that because I think the more people that know Anavex has multiple trials going the greater the likelihood of attracting inquiring minds.
You would make a very poor addict.
From the beginning I thought we'd be at around 100 million shares before revenues stopped the bleeding so I'm pretty darn happy with where the share count stands now.
What should we do in the interim?
Might they not present an Analysis of Cognitive Outcome Measures Relevant in AD from the PDD trial and nothing else and do a full presentation at a PD conference?
A 2 for 1 in regards to exposure.